CALT Calliditas Therapeutics
- 22.137
- -0.453-2.01%
- 22.300
- +0.163+0.74%
Calliditas Therapeutics News
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending slightly higher Wednesday morning, rising 0.10% to 1,427.23 on the S&P Europe Select ADR Index. From continental Europe
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
"We are delighted to participate in ERA and look forward to engaging with the leaders in the renal space," said Richard Philipson, Chief Medical Officer at Calliditas. "
Exploring Three Swedish Growth Companies With High Insider Ownership On The Swedish Exchange
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading
Telecoms stocks led European equities traded in the US as American depositary receipts slightly higher Tuesday morning, rising 0.15% to 1,420.65 on the S&P Europe Select ADR Index. From continental Eu
Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise
Calliditas Therapeutics (CALT) said Tuesday its partner Everest Medicines is offering Nefecon in China. China's National Medical Products Administration granted conditional approval for Nefecon in Nov
Calliditas' Partner Everest Medicines Starts Commercial Launch Of Nefecon In China
Calliditas' Partner Everest Medicines Starts Commercial Launch Of Nefecon In China
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending modestly higher late Wednesday morning, rising 0.34% to 1,399.71 on the S&P Europe Select ADR Index. From continental E
Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints
Calliditas Therapeutics (CALT) said Monday that data from a phase 2 trial of its drug candidate setanaxib in combination with pembrolizumab in patients with head and neck cancer met its secondary endp
Calliditas Therapeutics Reports Data From Phase 2 Study Of Setanaxib In Combination With Pembrolizumab For Head And Neck Cancer
Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in c
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading
European equities traded in the US as American depositary receipts were trending modestly higher Thursday morning, rising 0.25% to 1,364.91 on the S&P Europe Select ADR Index. From continental Europe,
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it
Stifel Nicolaus Sticks to Its Buy Rating for Calliditas Therapeutics (CALT)
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
European equities traded in the US as American depositary receipts were trending modestly higher Thursday morning, rising 0.24% to 1,364.10 on the S&P Europe Select ADR Index. From continental Europe,
Calliditas Therapeutics' 2023 Annual Report Published
Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available...
Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings
Calliditas Therapeutics (CALT) said Wednesday that an open-label extension, or OLE, study to its late-stage NefIgArd study showed a treatment response that was consistent with the NefIgArd study's fin
Calliditas Announces Positive NefIgArd Open Label Extension Results
STOCKHOLM, April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open-label extension (OLE) study to the P
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading
After closing out last week more than 2% lower, European equities traded in the US as American depositary receipts rebounded Monday morning, rising 1.09% to 1,340.58 on the S&P Europe Select ADR Index
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.46% to 1,330.20 on the S&P Europe Select ADR Index. Despite the gain, the index remains
Calliditas Therapeutics Presents Additional Data Analyses From Phase 3 NeflgArd Trial Of Nefecon In Primary IgA Nephropathy At ISN World Congress Of Nephrology 2024
Richard Philipson, Chief Medical Officer of Calliditas, said, "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European equities traded in the US as American depositary receipts kicked off the week trending moderately higher Monday morning, rising 0.53% to 1,352.74 on the S&P Europe Select ADR Index. From cont
Analysis
Price Target
No Data
